Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma

Oncogene

Volumn 34, Issue 13, 2015, Pages 1619-1628

  Li, X ^a,b   Liu, Y ^a   Granberg, K J ^a,c   Wang, Q ^b   Moore, L M ^a   Ji, P ^a   Gumin, J ^a   Sulman, E P ^a   Calin, G A ^a   Haapasalo, H ^c   Nykter, M ^c   Shmulevich, I ^d   Fuller, G N ^a   Lang, F F ^a   Zhang, W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MIRN491 MICRORNA, HUMAN; PROTEIN BCL X; SOMATOMEDIN BINDING PROTEIN 2;

ANIMAL; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; MALE; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ANIMALS; BCL-X PROTEIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MICE; MICRORNAS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84898518413     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.98     Document Type: Article

References (55)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001; 20: 173-193.
3. Testa JR, Liu Z, Feder M, Bell DW, Balsara B, Cheng JQ, et al. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet 1997; 95: 20-32.
4. Sato M, Takahashi K, Nagayama K, Arai Y, Ito N, Okada M, et al. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer 2005; 44: 405-414.
5. Kohno T, Yokota J. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. DNA Repair (Amst) 2006; 5: 1273-1281.
6. Sasaki S, Kitagawa Y, Sekido Y, Minna JD, Kuwano H, Yokota J, et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 2003; 22: 3792-3798.
7. Gursky S, Olopade OI, Rowley JD. Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. Cancer Genet Cytogenet 2001; 129: 93-101.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
10. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010; 127: 1072-1080.
11. Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 2011; 1411: 108-115.
12. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123: 855-865.
13. Moore LM, Kivinen V, Liu Y, Annala M, Cogdell D, Liu X, et al. Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma. J Pathol 2013; 229: 449-459.
14. Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF. Adenovirusmediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ 2000; 11: 373-384.
15. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, et al. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 2005; 26: 1217-1226.
16. Zhang W, Fuller G. IGFBP2 as a brain tumor oncogene. Cancer Biol Ther 2007; 6: 995-996.
17. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulinlike growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282: 18634-18644.
18. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005; 4: 7.
19. Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasionenhancing genes. Cancer Res 2003; 63: 4315-4321.
20. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008; 4: 427-435.
21. Hsieh D, Hsieh A, Stea B, Ellsworth R. IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun 2010; 397: 367-372.
22. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
23. Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 2009; 284: 7138-7148.
24. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
25. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
26. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 2007; 104: 11736-11741.
27. Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 2011; 71: 7125-7134.
28. Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer 2014; 33: 1-3.
29. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
30. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
31. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133-142.
32. Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol Cancer Ther 2011; 10: 1102-1112.
33. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for highgrade gliomas. Proc Natl Acad Sci USA 2009; 106: 16675-16679.
34. Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006; 281: 14085-14091.
35. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012; 481: 190-194.
36. Feng J, Kim ST, Liu W, Kim JW, Zhang Z, Zhu Y, et al. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. Cancer 2012; 118: 232-240.
37. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc Natl Acad Sci USA 2012; 109: 3475-3480.
38. Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, et al. KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. Brain 2012; 135: 1027-1041.
39. Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 2008; 283: 10958-10966.
40. Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, Holland EC, et al. Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol 2010; 97: 323-337.
41. Beukelaers P, Vandenbosch R, Caron N, Nguyen L, Belachew S, Moonen G, et al. Cdk6-dependent regulation of G(1) length controls adult neurogenesis. Stem Cells 2011; 29: 713-724.
42. Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W, et al. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells. Cancer Biother Radiopharm 2011; 26: 77-83.
43. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
44. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010; 9: 1031-1036.
45. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, Dugas JC, Gill RM, Huillard E, et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene 2012; 31: 1884-1895.
46. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68: 3566-3572.
47. Hai C, Jin YM, Jin WB, Han ZZ, Cui MN, Piao XZ, et al. Application of mesenchymal stem cells as a vehicle to deliver replication-competent adenovirus for treating malignant glioma. Chin J Cancer 2012; 31: 233-240.
48. Bexell D, Svensson A, Bengzon J. Stem cell-based therapy for malignant glioma. Cancer Treat Rev 2013; 39: 358-365.
49. Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X, et al. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol Ther 2011; 19: 1161-1169.
50. Hwang do W, Son S, Jang J, Youn H, Lee S, Lee D, et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011; 32: 4968-4975.
51. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-1414.
52. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, et al. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 2010; 9: 2098-2108.
53. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821-828.
54. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262: 2050-2054.
55. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-11620.